FELDAN THERAPEUTICS - REPORTS PRELIMINARY PHASE 1 RESULTS FOR FLD-103 IN NODULAR BASAL CELL CARCINOMA, DEMONSTRATING A GENERALLY WELL-TOLERATED SAFETY PROFILE AND SIGNS OF CLINICAL ACTIVITY